BioLineRx Ltd.
BLRX
$4.24
-$0.33-7.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 5.13M | -3.19M | -5.82M | 484.00K | -696.00K |
| Total Depreciation and Amortization | 165.00K | 1.78M | 840.00K | 476.00K | 897.00K |
| Total Amortization of Deferred Charges | 702.00K | 742.00K | -- | -- | -- |
| Total Other Non-Cash Items | -8.07M | -7.53M | -1.41M | -5.09M | -3.54M |
| Change in Net Operating Assets | -513.00K | -410.00K | -3.43M | -7.20M | -10.77M |
| Cash from Operations | -2.59M | -8.61M | -9.83M | -11.33M | -14.11M |
| Capital Expenditure | -- | 6.00K | 0.00 | -27.00K | -32.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -8.18M | 11.15M | 10.18M | -8.62M | 16.72M |
| Cash from Investing | -8.18M | 11.16M | 10.18M | -8.65M | 16.69M |
| Total Debt Issued | -- | 0.00 | 0.00 | 19.22M | -- |
| Total Debt Repaid | -1.25M | -12.10M | -1.04M | -909.00K | -894.00K |
| Issuance of Common Stock | 10.70M | 10.99M | -- | 5.57M | -- |
| Repurchase of Common Stock | -- | -- | -180.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 9.45M | -1.11M | -1.22M | 23.88M | -894.00K |
| Foreign Exchange rate Adjustments | -82.00K | 162.00K | 81.00K | -272.00K | 51.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.40M | 1.60M | -787.00K | 3.63M | 1.74M |